Asset Details
Do you wish to reserve the book?
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Do you wish to request the book?
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Phage Display Derived Monoclonal Antibodies: From Bench to Bedside
2020
Overview
Monoclonal antibodies (mAbs) have become one of the most important classes of biopharmaceutical products, and they continue to dominate the universe of biopharmaceutical markets in terms of approval and sales. They are the most profitable single product class, where they represent six of the top ten selling drugs. At the beginning of the 1990s, an
antibody selection technology known as antibody phage display was developed by John McCafferty and Sir. Gregory Winter that enabled the discovery of human antibodies for diverse applications, particularly antibody-based drugs. They created combinatorial antibody libraries on filamentous phage to be utilized for generating antigen specific antibodies in a matter of weeks. Since then, more than 70 phage-derived antibodies entered clinical studies and 14 of them have been approved. These antibodies are indicated for cancer, and non-cancer medical conditions, such as inflammatory, optical, infectious, or immunological diseases. This review will illustrate the utility of phage display as a powerful platform for therapeutic antibodies discovery and describe in detail all the approved mAbs derived from phage display.
Publisher
Frontiers Media SA,Frontiers Media S.A
Subject
/ Antibodies, Monoclonal - genetics
/ Antibodies, Monoclonal - immunology
/ Antibodies, Monoclonal - pharmacology
/ Antibodies, Monoclonal - therapeutic use
/ Antibody Specificity - genetics
/ Antibody Specificity - immunology
/ Antigens
/ Antineoplastic Agents, Immunological - pharmacology
/ Antineoplastic Agents, Immunological - therapeutic use
/ Cell Surface Display Techniques
/ Cloning
/ Drug Evaluation, Preclinical
/ E coli
/ Genes
/ Genomes
/ High-Throughput Screening Assays
/ Humans
/ Peptides
/ Phages
/ Proteins
/ R&D
